Navigation Links
New Chief Executive Officer and Vice President Commercial Operations USA at the Helsinn Group's American subsidiary, Helsinn Therapeutics (U.S.) Inc.

LUGANO, Switzerland, September 9 /PRNewswire/ -- As part of the Helsinn Group's development strategy, William Mann, PhD, has been appointed as new CEO in the American subsidiary, Helsinn Therapeutics (U.S.) Inc. William Mann, PhD, was already Chief Operating Officer of the recently acquired Helsinn Therapeutics, and has held leadership positions in a Swiss multinational with positions in Business Development and in Research.

Moreover, Helsinn announces that Mr. William Brown has been hired as Vice President Commercial Operations USA, to build a Helsinn Therapeutics direct sales structure in the United States. Mr. Brown has experience in multinational groups and in the management of Supportive Care, having previously managed the product Aloxi in MGI Pharma.

Dr. Riccardo Braglia, the Helsinn group's CEO said, "Helsinn wishes to implement a new group growth strategy in the United States, placing more and more importance on the project development and acquisition of new business expertise. The appointments of William Mann and William Brown will allow us to consolidate Helsinn's US business, the projects currently in development in cancer supportive care and in gastrointestinal areas and will lay the foundations for further development in North America also from a commercial point of view."

About Helsinn Group

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's unique business model is focused on the licensing of pharmaceuticals and medical devices in therapeutic niche areas. The Group in-licenses early stage new chemical entities, completes their development from the performance of pre-clinical/clinical studies and Chemistry, Manufacturing and Control (CMC) development, to the filing for and attainment of their market approval worldwide.

Helsinn's products are sold directly, through the Group subsidiaries, or eventually out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how, and assisted and supported with a full range of product and scientific management services, including commercial, regulatory, financial, legal and medical marketing advice.

The active pharmaceutical ingredients and the finished dosage forms are manufactured at Helsinn's cGMP facilities in Switzerland and Ireland, and supplied worldwide to its customers. Helsinn is the worldwide licensor of palonosetron, a second generation 5-HT3 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) and of post-operative nausea and vomiting (PONV) in patients with cancer, and of the original nimesulide, a non-steroidal anti-inflammatory drug (NSAID) distributed in more than 50 countries worldwide.

Helsinn, with a workforce of around 450 employees in Switzerland, Ireland and USA, reported a 2008 turnover of over CHF 280.3 million (about EUR 178 million), covering 75 countries worldwide, with over 20% of this turnover invested in R&D.

For more information about Helsinn Group, please visit the website:

    Contact person at Helsinn Healthcare SA:
    Paola Bonvicini
    Head of Communication & Press Office
    Tel.: +41-91-985-21-21

SOURCE Helsinn Healthcare SA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Mediware Names Thomas K. Mann Chief Executive Officer
4. Dr. Allen Woolf Appointed Chief Medical Officer For CIGNA Group Insurance
5. Sean P. McLaughlin Joins Red Cross as Chief of Operations Support
6. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
7. Coalition America Announces Addition of Mollie Gordon Brown as Chief Strategy Officer
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Karen Vigil Named Senior Vice President and Chief Executive Officer, Blue Shield of Californias Individual, Small Group, and Government Business Unit
10. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
11. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
Post Your Comments:
(Date:11/25/2015)... Missouri (PRWEB) , ... November 25, 2015 , ... ... HEAL, will provide scholarships for people struggling with eating disorders as a result ... from the second annual event, held at Fox Run Golf Club in Eureka, ...
(Date:11/25/2015)... ... November 25, 2015 , ... An unlikely combination of recycled ... way for homeless people to have a more dignified and comfortable night’s sleep. ... they are repurposing plastic bags into sleeping mats for the homeless. The ...
(Date:11/25/2015)... Mateo, CA (PRWEB) , ... November 25, 2015 , ... ... in prizes were awarded to winners of the Create Real Impact awards. California ... creative expression to help stem the tide of distracted and reckless driving, the number ...
(Date:11/24/2015)... GA (PRWEB) , ... November 24, 2015 , ... Dr. ... to now offer laser services to many of his patients. Dr. Afferica now uses ... designed to reduce the amount of time the doctor uses other traditional cutting tools, ...
(Date:11/24/2015)... SAN FRANCISCO, CA (PRWEB) , ... November 24, ... ... launched half-cup sizes, has launched their Black Friday sale a week early, offering ... ThirdLove continues to transform the intimate apparel industry through both mobile fit technology ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... , November 25, 2015 ... Investors"), pursuant to which BioLight and the New Investors ... Ltd. subsidiary ("IOPtima") via a private placement. The financing ... its innovative IOPtimate™ system used in the treatment of ... pathway process for the IOPtimate™ system with the U.S. ...
(Date:11/25/2015)... 25, 2015 --> ... eine Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, ... ENS-Lyon innehaben, an Enyo Pharma vergeben haben. ... Leben gerufenen und von Edelris gemeinsam mit seinen Partnern ... Behandlungsziel für HBV identifiziert, und es wurden neue Inhaltsstoffe ...
(Date:11/24/2015)... Calif. , Nov. 24, 2015 /PRNewswire/ ... leader in non-invasive genetic testing and the ... that it will present at the 27 ... York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew Rabinowitz, ... Company,s financial results, business activities and financial ...
Breaking Medicine Technology: